(VIANEWS) – Progressive Corporation (PGR), ANI Pharmaceuticals (ANIP), Astrazeneca (AZN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Progressive Corporation (PGR)
18.2% sales growth and 29.92% return on equity
The Progressive Corporation, an insurance holding company, provides personal and commercial auto, personal residential and commercial property, business related general liability, and other specialty property-casualty insurance products and related services in the United States. It operates in three segments: Personal Lines, Commercial Lines, and Property. The Personal Lines segment writes insurance for personal autos and recreational vehicles (RV). This segment's products include personal auto insurance; and special lines products, including insurance for motorcycles, ATVs, RVs, watercrafts, snowmobiles, and related products. The Commercial Lines segment provides auto-related liability and physical damage insurance, and business-related general liability and property insurance for autos, vans, and pick-up trucks used by small businesses, as well as non-fleet taxis, black-car services, and airport taxis; tractors, trailers, and straight trucks primarily used by regional general freight and expeditor-type businesses, and long-haul operators; dump trucks used by light contractors and heavy constructions; log trucks and garbage trucks used by dirt, sand and gravel, logging, garbage/debris removal, and coal-type businesses; and tow trucks and wreckers used in towing services and gas/service station businesses. The Property segment writes residential property insurance for homeowners, other property owners, and renters, as well as offers manufactured homes, personal umbrella insurance, and primary and excess flood insurance. The company offers policy issuance and claims adjusting services; acts as an agent to homeowners, general liability, workers' compensation insurance, and other products; and reinsurance services. It sells its products through independent insurance agencies, as well as through mobile applications and over the phone. The Progressive Corporation was founded in 1937 and is headquartered in Mayfield Village, Ohio.
Earnings Per Share
As for profitability, Progressive Corporation has a trailing twelve months EPS of $6.57.
PE Ratio
Progressive Corporation has a trailing twelve months price to earnings ratio of 31.04. Meaning, the purchaser of the share is investing $31.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.92%.
Sales Growth
Progressive Corporation’s sales growth is 15.7% for the present quarter and 18.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 542.5% and 11.5%, respectively.
2. ANI Pharmaceuticals (ANIP)
12.5% sales growth and 4.72% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $0.85.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 77.01. Meaning, the purchaser of the share is investing $77.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.72%.
Yearly Top and Bottom Value
ANI Pharmaceuticals’s stock is valued at $65.46 at 16:22 EST, under its 52-week high of $70.81 and way higher than its 52-week low of $37.06.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 15.4% and a negative 15.6%, respectively.
Moving Average
ANI Pharmaceuticals’s worth is higher than its 50-day moving average of $65.37 and way above its 200-day moving average of $58.68.
Volume
Today’s last reported volume for ANI Pharmaceuticals is 26015 which is 82.1% below its average volume of 145382.
Previous days news about ANI Pharmaceuticals(ANIP)
- According to Zacks on Friday, 10 May, "Some better-ranked stocks in the overall healthcare sector include ANI Pharmaceuticals (ANIP Quick QuoteANIP – Free Report) , Ligand Pharmaceuticals (LGND Quick QuoteLGND – Free Report) and United Therapeutics (UTHR Quick QuoteUTHR – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. ", "Earnings of ANI Pharmaceuticals beat estimates in each of the last four quarters. "
- According to Zacks on Friday, 10 May, "Some top-ranked stocks in the drug/biotech sector are ANI Pharmaceuticals (ANIP Quick QuoteANIP – Free Report) and Ligand Pharmaceuticals (LGND Quick QuoteLGND – Free Report) , both carrying a Zacks Rank #2 (Buy). ", "Earnings of ANI Pharmaceuticals beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 109.06 %."
- According to Zacks on Friday, 10 May, "Some better-ranked stocks in the overall healthcare sector include ANI Pharmaceuticals (ANIP Quick QuoteANIP – Free Report) , Ligand Pharmaceuticals (LGND Quick QuoteLGND – Free Report) and United Therapeutics (UTHR Quick QuoteUTHR – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. ", "Earnings of ANI Pharmaceuticals beat estimates in each of the last four quarters. "
3. Astrazeneca (AZN)
12.4% sales growth and 17.29% return on equity
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Earnings Per Share
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.9.
PE Ratio
Astrazeneca has a trailing twelve months price to earnings ratio of 36.28. Meaning, the purchaser of the share is investing $36.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.29%.
Moving Average
Astrazeneca’s worth is below its 50-day moving average of $69.47 and higher than its 200-day moving average of $67.21.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 22, 2024, the estimated forward annual dividend rate is 1.45 and the estimated forward annual dividend yield is 1.88%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 47.61B for the twelve trailing months.
Yearly Top and Bottom Value
Astrazeneca’s stock is valued at $68.93 at 16:22 EST, way below its 52-week high of $77.94 and way higher than its 52-week low of $60.47.
4. Kadant (KAI)
11.5% sales growth and 15.35% return on equity
Kadant Inc. supplies equipment and critical components worldwide. The company's Papermaking Systems segment develops, manufactures, and markets custom-engineered stock-preparation systems and equipment for the preparation of wastepaper for conversion into recycled paper and balers, as well as related equipment used in the processing of recyclable and waste materials; and fluid-handling systems and equipment used in industrial piping systems to compensate for movement, as well as to transfer fluid, power, and data. This segment also offers doctoring systems and equipment, and related consumables to enhance the operation of paper machines and other industrial processes; and filtration and cleaning systems for draining, purifying, and recycling process water, as well as cleaning fabrics, belts, and rolls in various process industries. Its Wood Processing Systems segment develops, manufactures, and markets debarkers, stranders, chippers, logging machinery, and related equipment used in the harvesting and production of lumber and oriented strand board, an engineered wood panel product used primarily in home construction. The company's Material Handling Systems segment develops, manufactures, and markets material handling equipment and systems, such as idler rolls, conveyors, vibratory screens, and flow aids to various process industries, including mining, aggregates, food processing, packaging, and pulp and paper industries. It also manufactures and sells biodegradable absorbent granules for use as carriers in agricultural, home lawn and garden, professional lawn, and turf and ornamental applications, as well as for oil and grease absorption. The company was formerly known as Thermo Fibertek Inc. and changed its name to Kadant Inc. in July 2001. Kadant Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.
Earnings Per Share
As for profitability, Kadant has a trailing twelve months EPS of $9.6.
PE Ratio
Kadant has a trailing twelve months price to earnings ratio of 29.95. Meaning, the purchaser of the share is investing $29.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.35%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 976.89M for the twelve trailing months.
